Pub Date : 2024-07-05DOI: 10.4274/balkanmedj.galenos.2024.2024-5-78
Andaç Salman, Ana M Giménez-Arnau
Atopic dermatitis (AD) is a chronic inflammatory condition that significantly affects the quality of life of both patients and their families or caregivers. Recently, treatment for moderate-to-severe AD were limited to conventional immunosuppressive therapies. However, currently, with the approval of biologic treatments and oral small molecules in the past decade, the effective and safe management of patients with AD is possible. Despite these advancements, challenges and unmet needs in clinical practice remain. This includes patients who do not respond well to or cannot tolerate existing treatment options and inadequate therapies that can modify the disease course. This review aimed to provide an overview of the current treatment approach for AD, highlight the current challenges in treatment, and discuss the rationale for novel treatment options and emerging evidence on systemic treatment options for AD.
特应性皮炎(AD)是一种慢性炎症,严重影响患者及其家人或护理人员的生活质量。最近,中重度特应性皮炎的治疗仅限于传统的免疫抑制疗法。然而,随着生物疗法和口服小分子药物在过去十年中获得批准,对 AD 患者进行有效、安全的治疗成为可能。尽管取得了这些进步,但临床实践中的挑战和未满足的需求依然存在。这包括对现有治疗方案反应不佳或无法耐受的患者,以及可改变病程的疗法不足。本综述旨在概述当前的AD治疗方法,强调当前治疗面临的挑战,并讨论新型治疗方案的原理以及AD系统性治疗方案的新证据。
{"title":"Emerging Systemic Treatment Options in Atopic Dermatitis.","authors":"Andaç Salman, Ana M Giménez-Arnau","doi":"10.4274/balkanmedj.galenos.2024.2024-5-78","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-5-78","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory condition that significantly affects the quality of life of both patients and their families or caregivers. Recently, treatment for moderate-to-severe AD were limited to conventional immunosuppressive therapies. However, currently, with the approval of biologic treatments and oral small molecules in the past decade, the effective and safe management of patients with AD is possible. Despite these advancements, challenges and unmet needs in clinical practice remain. This includes patients who do not respond well to or cannot tolerate existing treatment options and inadequate therapies that can modify the disease course. This review aimed to provide an overview of the current treatment approach for AD, highlight the current challenges in treatment, and discuss the rationale for novel treatment options and emerging evidence on systemic treatment options for AD.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":"41 4","pages":"239-247"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05Epub Date: 2024-05-22DOI: 10.4274/balkanmedj.galenos.2024.2024-2-79
Ana V Pejcic, Nemanja Z Petrovic, Milan D Djordjic, Milos N Milosavljevic
Background: Premature rupture of membranes (PROM) is defined as the leakage of amniotic fluid before the onset of labor and delivery contractions. Some studies found that women who experienced PROM had significantly lower vitamin C blood levels than those who did not, while others found no significant differences. Previous systematic reviews and meta-analyses on the efficacy of vitamin C in the prevention of PROM had conflicting results.
Aims: Conduct a systematic review and meta-analysis to determine if there was a significant difference in vitamin C blood levels in women who had PROM versus the control group who did not and to determine if vitamin C supplements could help prevent it.
Study design: Systematic review and meta-analysis.
Methods: We registered our protocol with PROSPERO (CRD42022371644). We searched PubMed/MEDLINE, Web of Science, and Scopus through February 15, 2024. Additionally, backward and forward citation searches were conducted. Studies were selected based on predetermined inclusion and exclusion criteria. Meta-Essentials: Workbooks for Meta-Analysis (version 1.5) was used for analysis.
Results: Twenty-five studies (26 reports) met all eligibility criteria, with 18 studies (18 reports) assessing vitamin C levels and seven studies (eight reports) evaluating efficacy. Women with PROM, whether preterm or term, had significantly lower vitamin C levels [Hedges’ g, -1.48; 95% confidence interval (CI): -2.82, -0.14; p = 0.020; I2 = 94.08%) and specifically preterm PROM after removing the outlying study [Hedges’ g, -1.29; 95% CI: -1.85, -0.73; p < 0.001; I2 = 87.35%). Vitamin C supplementation significantly reduced the risk of preterm or term PROM [risk ratio (RR), 0.57; 95% CI: 0.39, 0.81; p < 0.001; I2 = 12.17%), particularly for preterm PROM (RR, 0.67; 95% CI: 0.45, 0.99; p = 0.001; I2 = 0.00%). There were no significant differences in vitamin C levels between women with term PROM and controls, and there were no differences in the risk of developing term PROM between women taking vitamin C supplements and controls. Results were not robust in all sensitivity analyses.
Conclusion: Women with PROM, particularly those who developed it preterm, appear to have significantly lower vitamin C levels, and vitamin C supplementation appears to be effective in reducing the risk of PROM, particularly preterm PROM. More high-quality studies with low risk of bias, more homogenous, and larger samples are needed to confirm these findings.
背景:胎膜早破(PROM)是指在分娩和宫缩开始之前羊水流出。一些研究发现,经历过胎膜早破的妇女血液中的维生素 C 含量明显低于未经历过的妇女,而另一些研究则发现两者之间没有明显差异。目的:我们旨在进行一项系统回顾和荟萃分析,以确定发生过PROM的产妇与未发生PROM的对照组相比,维生素C血液水平是否存在显著差异,并确定维生素C补充剂是否有助于预防PROM:研究设计:系统综述和荟萃分析:我们在 PROSPERO(CRD42022371644)上注册了我们的方案。我们检索了 PubMed/MEDLINE、Web of Science 和 Scopus,检索期至 2024 年 2 月 15 日。此外,我们还进行了前向和后向引文检索。研究根据预先确定的纳入和排除标准进行筛选。Meta-Essentials:使用《Meta-Essentials:Meta 分析工作手册》(1.5 版)进行分析:25项研究(26份报告)符合所有资格标准,其中18项研究(18份报告)评估了维生素C水平,7项研究(8份报告)评估了疗效。无论是早产儿还是足月儿,PROM 妇女的维生素 C 水平都明显较低[Hedges' g,-1.48;95% 置信区间(CI):-2.82,-0.14;p = 0.020;I2 = 94.08%],剔除离群研究后,PROM 妇女的维生素 C 水平尤其较低[Hedges' g,-1.29;95% CI:-1.85,-0.73;p < 0.001;I2 = 87.35%]。补充维生素 C 可显著降低早产或足月 PROM 的风险[风险比 (RR),0.57;95% CI:0.39,0.81;p < 0.001;I2 = 12.17%],尤其是早产 PROM(RR,0.67;95% CI:0.45,0.99;p = 0.001;I2 = 0.00%)。足月 PROM 妇女与对照组妇女的维生素 C 水平无明显差异,服用维生素 C 补充剂的妇女与对照组妇女发生足月 PROM 的风险也无差异。所有敏感性分析的结果均不可靠:结论:患有 PROM(尤其是早产 PROM)的妇女的维生素 C 水平似乎明显较低,补充维生素 C 似乎能有效降低 PROM(尤其是早产 PROM)的风险。要证实这些发现,还需要进行更多高质量、低偏倚风险、同质性更强、样本更大的研究。
{"title":"Vitamin C Levels in Pregnant Women and the Efficacy of Vitamin C Supplements in Preventing Premature Rupture of Membranes: A Systematic Review and Meta-Analysis","authors":"Ana V Pejcic, Nemanja Z Petrovic, Milan D Djordjic, Milos N Milosavljevic","doi":"10.4274/balkanmedj.galenos.2024.2024-2-79","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-2-79","url":null,"abstract":"<p><strong>Background: </strong>Premature rupture of membranes (PROM) is defined as the leakage of amniotic fluid before the onset of labor and delivery contractions. Some studies found that women who experienced PROM had significantly lower vitamin C blood levels than those who did not, while others found no significant differences. Previous systematic reviews and meta-analyses on the efficacy of vitamin C in the prevention of PROM had conflicting results.</p><p><strong>Aims: </strong>Conduct a systematic review and meta-analysis to determine if there was a significant difference in vitamin C blood levels in women who had PROM versus the control group who did not and to determine if vitamin C supplements could help prevent it.</p><p><strong>Study design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>We registered our protocol with PROSPERO (CRD42022371644). We searched PubMed/MEDLINE, Web of Science, and Scopus through February 15, 2024. Additionally, backward and forward citation searches were conducted. Studies were selected based on predetermined inclusion and exclusion criteria. Meta-Essentials: Workbooks for Meta-Analysis (version 1.5) was used for analysis.</p><p><strong>Results: </strong>Twenty-five studies (26 reports) met all eligibility criteria, with 18 studies (18 reports) assessing vitamin C levels and seven studies (eight reports) evaluating efficacy. Women with PROM, whether preterm or term, had significantly lower vitamin C levels [Hedges’ g, -1.48; 95% confidence interval (CI): -2.82, -0.14; <i>p</i> = 0.020; <i>I<sup>2</sup></i> = 94.08%) and specifically preterm PROM after removing the outlying study [Hedges’ g, -1.29; 95% CI: -1.85, -0.73; <i>p</i> < 0.001; <i>I<sup>2</sup></i> = 87.35%). Vitamin C supplementation significantly reduced the risk of preterm or term PROM [risk ratio (RR), 0.57; 95% CI: 0.39, 0.81; <i>p</i> < 0.001; <i>I<sup>2</sup></i> = 12.17%), particularly for preterm PROM (RR, 0.67; 95% CI: 0.45, 0.99; <i>p</i> = 0.001; <i>I<sup>2</sup></i> = 0.00%). There were no significant differences in vitamin C levels between women with term PROM and controls, and there were no differences in the risk of developing term PROM between women taking vitamin C supplements and controls. Results were not robust in all sensitivity analyses.</p><p><strong>Conclusion: </strong>Women with PROM, particularly those who developed it preterm, appear to have significantly lower vitamin C levels, and vitamin C supplementation appears to be effective in reducing the risk of PROM, particularly preterm PROM. More high-quality studies with low risk of bias, more homogenous, and larger samples are needed to confirm these findings.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":" ","pages":"248-260"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141074359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.4274/balkanmedj.galenos.2024.2024-140624
Hüseyin Güdücüoğlu
{"title":"A One Health Approach to Zoonotic Diseases in Extraordinary and Ordinary Circumstances.","authors":"Hüseyin Güdücüoğlu","doi":"10.4274/balkanmedj.galenos.2024.2024-140624","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-140624","url":null,"abstract":"","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":"41 4","pages":"236-238"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05Epub Date: 2024-05-20DOI: 10.4274/balkanmedj.galenos.2024.2024-010424
Sezgi Sarıkaya Solak, Fatih Göktay
{"title":"The Promising Role of Artificial Intelligence in Nail Diseases","authors":"Sezgi Sarıkaya Solak, Fatih Göktay","doi":"10.4274/balkanmedj.galenos.2024.2024-010424","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-010424","url":null,"abstract":"","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":" ","pages":"234-235"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141065330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05Epub Date: 2024-06-03DOI: 10.4274/balkanmedj.galenos.2024.2024-2-115
Fatma Yeşil, Çağrı Çövener Özçelik
Background: Type 1 diabetes is one of the most common chronic diseases in children. Wearable technology (insulin pumps and continuous glucose monitoring devices) that makes diabetes management relatively simple, in addition to education and follow-ups, enhances the quality of life and health of individuals with diabetes.
Aims: To evaluate the impact of wearable technology on metabolic management and the quality of life in children and adolescents with type 1 diabetes.
Study design: Systematic review and meta-analysis.
Methods: The Preferred Reporting System for Systematic Reviews and Meta-Analyses was used to conduct a systematic review and meta-analysis. PubMed, Web of Science, MEDLINE, Cochrane Library, EBSCO, Ulakbim and Google Scholar were searched in July 2022 and July 2023 using predetermined keywords. The methodological quality of the studies was evaluated using the Joanna Briggs Institute’s Critical Appraisal Checklists for randomized controlled experimental and cross-sectional studies. The meta-analysis method was used to pool the data.
Results: Eleven studies published between 2011 and 2022 were included. The total sample size of the included studies was 1,853. The meta-analysis revealed that the decrease in hemoglobin A1C (HbA1c) level in those using wearable technology was statistically significant [mean difference (MD): -0.33, Z = 2.54, p = 0.01]. However, the technology had no effect on the quality of life [standardized mean difference (SMD): 0.44, Z = 1.72, p = 0.09]. The subgroup analyses revealed that the decrease in the HbA1c level occurred in the cross-sectional studies (MD: -0.49, Z = 2.54, p = 0.01) and the 12-19 (MD = 0.59, Z = 4.40, p < 0.001) and 4-18 age groups (MD: -0.31, Z = 2.56, p = 0.01). The subgroup analyses regarding the quality of life revealed that there was no difference according to the research design. However, the quality of life was higher in the wearable technology group than in the control group in the 8-12 and 4-18 age groups (SMD: 1.32, Z = 2.31, p = 0.02 and SMD: 1.00, Z = 5.76, p < 0.001, respectively).
Conclusion: Wearable technology effectively reduces the HbA1c levels in children and adolescents with type 1 diabetes in some age groups. However, it does not affect the quality of life.
{"title":"Effect of Wearable Technology on Metabolic Control and the Quality of Life in Children and Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis","authors":"Fatma Yeşil, Çağrı Çövener Özçelik","doi":"10.4274/balkanmedj.galenos.2024.2024-2-115","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-2-115","url":null,"abstract":"<p><strong>Background: </strong>Type 1 diabetes is one of the most common chronic diseases in children. Wearable technology (insulin pumps and continuous glucose monitoring devices) that makes diabetes management relatively simple, in addition to education and follow-ups, enhances the quality of life and health of individuals with diabetes.</p><p><strong>Aims: </strong>To evaluate the impact of wearable technology on metabolic management and the quality of life in children and adolescents with type 1 diabetes.</p><p><strong>Study design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>The Preferred Reporting System for Systematic Reviews and Meta-Analyses was used to conduct a systematic review and meta-analysis. PubMed, Web of Science, MEDLINE, Cochrane Library, EBSCO, Ulakbim and Google Scholar were searched in July 2022 and July 2023 using predetermined keywords. The methodological quality of the studies was evaluated using the Joanna Briggs Institute’s Critical Appraisal Checklists for randomized controlled experimental and cross-sectional studies. The meta-analysis method was used to pool the data.</p><p><strong>Results: </strong>Eleven studies published between 2011 and 2022 were included. The total sample size of the included studies was 1,853. The meta-analysis revealed that the decrease in hemoglobin A1C (HbA1c) level in those using wearable technology was statistically significant [mean difference (MD): -0.33, Z = 2.54, <i>p</i> = 0.01]. However, the technology had no effect on the quality of life [standardized mean difference (SMD): 0.44, Z = 1.72, <i>p</i> = 0.09]. The subgroup analyses revealed that the decrease in the HbA1c level occurred in the cross-sectional studies (MD: -0.49, Z = 2.54, <i>p</i> = 0.01) and the 12-19 (MD = 0.59, Z = 4.40, <i>p</i> < 0.001) and 4-18 age groups (MD: -0.31, Z = 2.56, <i>p</i> = 0.01). The subgroup analyses regarding the quality of life revealed that there was no difference according to the research design. However, the quality of life was higher in the wearable technology group than in the control group in the 8-12 and 4-18 age groups (SMD: 1.32, Z = 2.31, <i>p</i> = 0.02 and SMD: 1.00, Z = 5.76, <i>p</i> < 0.001, respectively).</p><p><strong>Conclusion: </strong>Wearable technology effectively reduces the HbA1c levels in children and adolescents with type 1 diabetes in some age groups. However, it does not affect the quality of life.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":" ","pages":"261-271"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141198575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.4274/balkanmedj.galenos.2024.2024-4-91
Ali Cem Yekdeş, Didem Han Yekdeş, Ülfiye Çelikkalp, Galip Ekuklu
Background: Breast cancer is the leading cause of cancer-related mortality in women in Türkiye.
Aims: Explore the trends in female breast cancer mortality rates and the associated modifiable factors in Türkiye between 1990 and 2019.
Study design: Epidemiological descriptive analysis.
Methods: The database of the Global Burden of Disease study was used to obtain data regarding breast cancer-related mortality and modifiable (behavioral and metabolic) risk factors among women in Türkiye from 1990 to 2019. The average annual percentage change (AAPC) for female breast cancer mortality rates was computed using the Joinpoint regression method.
Results: From 1990 to 2009, the breast cancer mortality rates in Türkiye tended to increase [from 12.26/105 in 1990 to 12.65/105 in 2019; AAPC=0.1 "95% confidence interval (CI): 0.1-0.1"]. In terms of breast cancer mortality attributed to modifiable factors, a 3% increase was observed from 1990 (20.4%) to 2019 (23.1%), the highest contributor being high body mass index (3.19% in 1990 to 5.87% in 2019; AAPC=1.5; 95% CI: 1.3-1.5), followed by high fasting plasma glucose (5.01% in 1990 to 7.72% in 2019; AAPC=1.4; 95% CI: 1.3-1.5).
Conclusion: The proportion of breast cancer-related deaths attributed to metabolic factors has been increasing in Türkiye from 1990 to 2019. Therefore, health policies aimed at managing metabolic factors in women are warranted to reduce breast cancer-related mortality in Türkiye.
{"title":"Modifiable Risk Factors for Breast Cancer Mortality in Türkiye from 1990 to 2019: A Temporal Analysis of Global Burden of Disease Data.","authors":"Ali Cem Yekdeş, Didem Han Yekdeş, Ülfiye Çelikkalp, Galip Ekuklu","doi":"10.4274/balkanmedj.galenos.2024.2024-4-91","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-4-91","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the leading cause of cancer-related mortality in women in Türkiye.</p><p><strong>Aims: </strong>Explore the trends in female breast cancer mortality rates and the associated modifiable factors in Türkiye between 1990 and 2019.</p><p><strong>Study design: </strong>Epidemiological descriptive analysis.</p><p><strong>Methods: </strong>The database of the Global Burden of Disease study was used to obtain data regarding breast cancer-related mortality and modifiable (behavioral and metabolic) risk factors among women in Türkiye from 1990 to 2019. The average annual percentage change (AAPC) for female breast cancer mortality rates was computed using the Joinpoint regression method.</p><p><strong>Results: </strong>From 1990 to 2009, the breast cancer mortality rates in Türkiye tended to increase [from 12.26/105 in 1990 to 12.65/105 in 2019; AAPC=0.1 \"95% confidence interval (CI): 0.1-0.1\"]. In terms of breast cancer mortality attributed to modifiable factors, a 3% increase was observed from 1990 (20.4%) to 2019 (23.1%), the highest contributor being high body mass index (3.19% in 1990 to 5.87% in 2019; AAPC=1.5; 95% CI: 1.3-1.5), followed by high fasting plasma glucose (5.01% in 1990 to 7.72% in 2019; AAPC=1.4; 95% CI: 1.3-1.5).</p><p><strong>Conclusion: </strong>The proportion of breast cancer-related deaths attributed to metabolic factors has been increasing in Türkiye from 1990 to 2019. Therefore, health policies aimed at managing metabolic factors in women are warranted to reduce breast cancer-related mortality in Türkiye.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":"41 4","pages":"298-307"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05DOI: 10.4274/balkanmedj.galenos.2024.2024-2-66
Jialin Yang, Na Lin, Shuang Li, Zhanhai Dong, Deli Wang, Yong Liu, Yang Zhou, Hui Yuan
Background: Cannabidiol (CBD), extracted from Cannabis sativa, has anticancer, anti-inflammation, and analgesic effects. Nevertheless, its therapeutic effect and the mechanism by which it alleviates oral mucositis (OM) remain unclear.
Aims: To explore the impact of CBD on OM in mice and on human oral keratinocyte (HOK) cells.
Study design: Expiremental study.
Methods: The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, GeneCard, DisGeNET, and Gene Expression Omnibus databases were used to conduct therapeutic target gene screening for drugs against OM. Cytoscape software was used to build networks linking components, targets, and diseases. The STRING database facilitated analysis of intertarget action relationships, and the target genes were analyzed for Kyoto Encyclopedia of Genes and Genomes pathway enrichment. Occurrence of serum inflammation-related factors, hematoxylin and eosin staining, and immunohistochemistry were used to assess OM injury. Cell proliferation, migration, pyroptosis, and apoptosis of HOK cells under different treatments were assessed. Molecular mechanisms were elucidated through western blot and quantitative real-time polymerase chain reaction analyses.
Results: A total of 49 overlapping genes were pinpointed as potential targets, with NF-κB1, PIK3R1, NF-κBIA, and AKT1 being recognized as hub genes among them. Additionally, the PI3K/Akt/NF-κB and interleukin-17 signaling pathways were identified as relevant. Our in vivo experiments showed that CBD significantly reduced the proportion of lesion area, mitigated oral mucosal tissue lesions, and downregulated the expression levels of genes and levels of proteins, including NLRP3, P65, AKT, and PI3K. In vitro experiments indicated that CBD enhanced HOK cell proliferation and migration and reduced apoptosis through inhibition of the PI3K/Akt/NF-κB signaling pathway and pyroptosis.
Conclusion: Our findings suggest a novel mechanism for controlling OM, in which CBD suppresses the PI3K/Akt/NF-κB signaling pathway and pyroptosis, thereby mitigating OM symptoms.
背景:从大麻中提取的大麻二酚(CBD)具有抗癌、抗炎和镇痛作用。目的:探讨大麻二酚对小鼠口腔黏膜炎和人类口腔角朊细胞(HOK)的影响:研究设计:过期研究:利用中药系统药理学数据库和分析平台、GeneCard、DisGeNET和Gene Expression Omnibus数据库进行OM药物治疗靶基因筛选。Cytoscape软件用于构建连接成分、靶点和疾病的网络。STRING 数据库有助于分析靶点间的作用关系,并对靶基因进行了京都基因和基因组百科全书通路富集分析。血清炎症相关因子的出现、苏木精和伊红染色以及免疫组织化学被用来评估 OM 损伤。评估了不同处理下 HOK 细胞的增殖、迁移、热凋亡和凋亡情况。通过 Western 印迹和定量实时聚合酶链反应分析阐明了分子机制:结果:共有 49 个重叠基因被确定为潜在靶点,NF-κB1、PIK3R1、NF-κBIA 和 AKT1 被认为是其中的枢纽基因。此外,PI3K/Akt/NF-κB 和白细胞介素-17 信号通路也被认为是相关的。我们的体内实验表明,CBD 能显著降低病变面积比例,减轻口腔黏膜组织病变,并下调 NLRP3、P65、AKT 和 PI3K 等基因和蛋白质的表达水平。体外实验表明,CBD通过抑制PI3K/Akt/NF-κB信号通路和细胞凋亡,增强了HOK细胞的增殖和迁移,减少了细胞凋亡:我们的研究结果表明了一种控制 OM 的新机制,即 CBD 可抑制 PI3K/Akt/NF-κB 信号通路和细胞凋亡,从而减轻 OM 症状。
{"title":"Cannabidiol Alleviates Oral Mucositis by Inhibiting PI3K/Akt/NF-κB-Mediated Pyroptosis.","authors":"Jialin Yang, Na Lin, Shuang Li, Zhanhai Dong, Deli Wang, Yong Liu, Yang Zhou, Hui Yuan","doi":"10.4274/balkanmedj.galenos.2024.2024-2-66","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-2-66","url":null,"abstract":"<p><strong>Background: </strong>Cannabidiol (CBD), extracted from <i>Cannabis sativa</i>, has anticancer, anti-inflammation, and analgesic effects. Nevertheless, its therapeutic effect and the mechanism by which it alleviates oral mucositis (OM) remain unclear.</p><p><strong>Aims: </strong>To explore the impact of CBD on OM in mice and on human oral keratinocyte (HOK) cells.</p><p><strong>Study design: </strong>Expiremental study.</p><p><strong>Methods: </strong>The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, GeneCard, DisGeNET, and Gene Expression Omnibus databases were used to conduct therapeutic target gene screening for drugs against OM. Cytoscape software was used to build networks linking components, targets, and diseases. The STRING database facilitated analysis of intertarget action relationships, and the target genes were analyzed for Kyoto Encyclopedia of Genes and Genomes pathway enrichment. Occurrence of serum inflammation-related factors, hematoxylin and eosin staining, and immunohistochemistry were used to assess OM injury. Cell proliferation, migration, pyroptosis, and apoptosis of HOK cells under different treatments were assessed. Molecular mechanisms were elucidated through western blot and quantitative real-time polymerase chain reaction analyses.</p><p><strong>Results: </strong>A total of 49 overlapping genes were pinpointed as potential targets, with NF-κB1, PIK3R1, NF-κBIA, and AKT1 being recognized as hub genes among them. Additionally, the PI3K/Akt/NF-κB and interleukin-17 signaling pathways were identified as relevant. Our in vivo experiments showed that CBD significantly reduced the proportion of lesion area, mitigated oral mucosal tissue lesions, and downregulated the expression levels of genes and levels of proteins, including NLRP3, P65, AKT, and PI3K. In vitro experiments indicated that CBD enhanced HOK cell proliferation and migration and reduced apoptosis through inhibition of the PI3K/Akt/NF-κB signaling pathway and pyroptosis.</p><p><strong>Conclusion: </strong>Our findings suggest a novel mechanism for controlling OM, in which CBD suppresses the PI3K/Akt/NF-κB signaling pathway and pyroptosis, thereby mitigating OM symptoms.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":"41 4","pages":"286-297"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-05Epub Date: 2024-06-03DOI: 10.4274/balkanmedj.galenos.2024.2024-1-97
Sümeyye Koç, Sedat Şen, Yüksel Terzi, Ferah Kızılay, Serkan Demir, Dürdane Bekar Aksoy, Fatma Kurtuluş, Nuray Bilge, Egemen Idilman, Cihat Uzunköprü, Serdal Güngör, Vedat Çilingir, Özlem Ethemoğlu, Cavit Boz, Haluk Gümüş, Ahmet Kasım Kılıç, Ayşin Kısabay, Levent Sinan Bir, Ömer Faruk Turan, Aysun Soysal, Mesrure Köseoğlu, Gülnur Tekgöl Uzuner, Hasan Bayındır, Sibel Canbaz Kabay, Mustafa Çam, Vildan Yayla, Hüseyin Tan, Abdülcemal Özcan, Özlem Taşkapıoğlu, Muammer Korkmaz, Yusuf Tamam, Yılmaz İnanç, Hüsnü Efendi, Dilcan Kotan, Mehmet Fatih Yetkin, Adnan Burak Bilgiç, Hikmet Saçmacı, Serpil Demirci, Yahya Çelik, Turan Poyraz, Murat Terzi
Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited.
Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG.
Study design: Multicenter, retrospective, observational study.
Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study.
Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients.
Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.
{"title":"Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein","authors":"Sümeyye Koç, Sedat Şen, Yüksel Terzi, Ferah Kızılay, Serkan Demir, Dürdane Bekar Aksoy, Fatma Kurtuluş, Nuray Bilge, Egemen Idilman, Cihat Uzunköprü, Serdal Güngör, Vedat Çilingir, Özlem Ethemoğlu, Cavit Boz, Haluk Gümüş, Ahmet Kasım Kılıç, Ayşin Kısabay, Levent Sinan Bir, Ömer Faruk Turan, Aysun Soysal, Mesrure Köseoğlu, Gülnur Tekgöl Uzuner, Hasan Bayındır, Sibel Canbaz Kabay, Mustafa Çam, Vildan Yayla, Hüseyin Tan, Abdülcemal Özcan, Özlem Taşkapıoğlu, Muammer Korkmaz, Yusuf Tamam, Yılmaz İnanç, Hüsnü Efendi, Dilcan Kotan, Mehmet Fatih Yetkin, Adnan Burak Bilgiç, Hikmet Saçmacı, Serpil Demirci, Yahya Çelik, Turan Poyraz, Murat Terzi","doi":"10.4274/balkanmedj.galenos.2024.2024-1-97","DOIUrl":"10.4274/balkanmedj.galenos.2024.2024-1-97","url":null,"abstract":"<p><strong>Background: </strong>Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited.</p><p><strong>Aims: </strong>To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG.</p><p><strong>Study design: </strong>Multicenter, retrospective, observational study.</p><p><strong>Methods: </strong>Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study.</p><p><strong>Results: </strong>Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients.</p><p><strong>Conclusion: </strong>For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":" ","pages":"272-279"},"PeriodicalIF":1.9,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11588904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-05-03Epub Date: 2024-03-08DOI: 10.4274/balkanmedj.galenos.2024.2023-11-90
Mustafa Kemal Demir, Önder Ertem, Deniz Kılıç, Okan Akıncı, Özge Ecertaştan, Deniz Konya, Türker Kılıç
Functional or non-secretory ectopic pituitary neuroendocrine tumors (PitNET) can form around the sella turcica during the development of the adenohypophysis by differentiating and detaching from the pharyngeal roof. These tumors usually appear in the sphenoid sinus, clivus, cavernous sinus, infundibulum, and suprasellar cistern. Ectopic PitNETs typically display the characteristic magnetic resonance imaging findings of pituitary adenomas. However, preoperative diagnosis of PitNETs is usually challenging because of the variety of clinical and imaging presentations, locations, and sizes. Ectopic suprasellar PitNETs resemble mass lesions in the pituitary stalk. Ectopic cavernous sinus of PitNETs are typically microadenomas in the medial wall. Ectopic sphenoclival tumors are characterized by more aggressive tumor activity than the other ectopic PitNETs. Although ectopic PitNETs are exceedingly rare, they should be considered as a differential diagnosis for masses around the sella turcica. Treatment of the disease should be individualized and may include medical care, surgical resection, gamma-knife radiosurgery, and radiotherapy.
{"title":"Ectopic Pituitary Neuroendocrine Tumors/Adenomas Around the Sella Turcica","authors":"Mustafa Kemal Demir, Önder Ertem, Deniz Kılıç, Okan Akıncı, Özge Ecertaştan, Deniz Konya, Türker Kılıç","doi":"10.4274/balkanmedj.galenos.2024.2023-11-90","DOIUrl":"10.4274/balkanmedj.galenos.2024.2023-11-90","url":null,"abstract":"<p><p>Functional or non-secretory ectopic pituitary neuroendocrine tumors (PitNET) can form around the sella turcica during the development of the adenohypophysis by differentiating and detaching from the pharyngeal roof. These tumors usually appear in the sphenoid sinus, clivus, cavernous sinus, infundibulum, and suprasellar cistern. Ectopic PitNETs typically display the characteristic magnetic resonance imaging findings of pituitary adenomas. However, preoperative diagnosis of PitNETs is usually challenging because of the variety of clinical and imaging presentations, locations, and sizes. Ectopic suprasellar PitNETs resemble mass lesions in the pituitary stalk. Ectopic cavernous sinus of PitNETs are typically microadenomas in the medial wall. Ectopic sphenoclival tumors are characterized by more aggressive tumor activity than the other ectopic PitNETs. Although ectopic PitNETs are exceedingly rare, they should be considered as a differential diagnosis for masses around the sella turcica. Treatment of the disease should be individualized and may include medical care, surgical resection, gamma-knife radiosurgery, and radiotherapy.</p>","PeriodicalId":8690,"journal":{"name":"Balkan Medical Journal","volume":" ","pages":"167-173"},"PeriodicalIF":1.9,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11077925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140058610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}